Disease-free interval after primary treatment predicts prognosis of recurrent endometrial carcinoma

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4347-4352

  Ueda, Yutaka ^a   Matsumura, Yuki ^a   Egawa Takata, Tomomi ^a   Miyake, Takahito ^b   Miyatake, Takashi ^a   Yoshino, Kiyoshi ^a   Fujita, Masami ^a   Matsuzaki, Shinya ^a   Yokoyama, Takuhei ^a   Miyoshi, Yukari ^a   Yamasaki, Masato ^b   Enomoto, Takayuki ^a   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

Disease free interval; Endometrial cancer; Overall survival; Prognosis; Recurrence

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; DISEASE FREE SURVIVAL; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; INDEPENDENT VARIABLE; JAPAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 78650234995     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. DiSaia PJ and Creasman WT: Clinical Gynecologic Oncology (6th ed.). St. Louis: Mosby, pp. 137-67, 2002.
2. Berek JS: Novak's Gynecology (13th ed.): Baltimore: William and Wilkins, pp. 1143-85, 2002.
3. Aapro MS, van Wijk FH, Bolis G, Chevallier B, van der Burg ME, Poveda A, de Oliveira CF, Tumolo S, Scotto di Palumbo V, Piccart M, Franchi M, Zanaboni F, Lacave AJ, Fontanelli R, Favalli G, Zola P, Guastalla JP, Rosso R, Marth C, Nooij M, Presti M, Scarabelli C, Splinter TA, Ploch E, Beex LV, ten Bokkel Huinink W, Forni M, Melpignano M, Blake P, Kerbrat P, Mendiola C, Cervantes A, Goupil A, Harper PG, Madronal C, Namer M, Scarfone G, Stoot JE, Teodorovic I, Coens C, Vergote I and Vermorken JB. European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group: Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 14: 441-448, 2003.
4. Ueda Y, Enomoto T, Miyatake T, Egawa-Takata T, Ugaki H, Yoshino K, Fujita M and Kimura T: Endometrial carcinoma with extra-abdominal metastasis: improved prognosis following cytoreductive surgery. Ann Surg Oncol 17: 1111-1117, 2010.
5. Fung-Kee-Fung M, Dodge J, Elit L, Lukka H, Chambers A and Oliver T: Cancer Care Ontario Program in Evidence-based Care Gynecology Cancer Disease Site Group. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 10: 520-529, 2006.
6. Sears JD, Greven KM, Hoen HM and Randall ME: Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer. Cancer 74: 1303-1308, 1994.
7. Kuten A, Grigsby PW, Perez CA, Fineberg B, Garcia DM and Simpson JR: Results of radiotherapy in recurrent endometrial carcinoma: a retrospective analysis of 51 patients. Int J Radiat Oncol Biol Phys 17: 29-34, 1989.
8. Poulsen MG and Roberts SJ: The salvage of recurrent endometrial carcinoma in the vagina and pelvis. Int J Radiat Oncol Biol Phys 15: 809-813, 1988.
9. Vavra N, Denison U, Kucera H, Barrada M, Kurz C, Salzer H and Sevelda P: Prognostic factors related to recurrent endometrial carcinoma following initial surgery. Acta Obstet Gynecol Scand 72: 205-209, 1993.
10. Curran WJ Jr., Whittington R, Peters AJ and Fanning J: Vaginal recurrences of endometrial carcinoma: the prognostic value of staging by a primary vaginal carcinoma system. Int J Radiat Oncol Biol Phys 15: 803-808, 1988.
11. Rubin P, Gerle RD, Quick RS and Greenlaw RH: Significance of vaginal recurrence in endometrial carcinoma. Am J Roentgenol Radium Ther Nucl Med 89: 91-100, 1963.
12. Mandell LR, Nori D and Hilaris B: Recurrent stage I endometrial carcinoma: results of treatment and prognostic factors. Int J Radiat Oncol Biol Phys 11: 1103-1109, 1985.
13. Ackerman I, Malone S, Thomas G, Franssen E, Balogh J and Dembo A: Endometrial carcinoma - relative effectiveness of adjuvant irradiation vs. therapy reserved for relapse. Gynecol Oncol 60: 177-183, 1996.
14. Pirtoli L, Ciatto S, Cionini L, Taddei G and Colafranceschi M: Salvage with radiotherapy of postsurgical relapses of endometrial cancer. Tumori 66: 475-480, 1980.
15. Phillips GL, Prem KA, Adcock LL and Twiggs LB: Vaginal recurrence of adenocarcinoma of the endometrium. Gynecol Oncol 13: 323-328, 1982.
16. Jereczek-Fossa B, Badzio A and Jassem J: Recurrent endometrial cancer after surgery alone: results of salvage radiotherapy. Int J Radiat Oncol Biol Phys 48: 405-413, 2000.
17. Karagol H, Saip P, Uygun K, Kucucuk S, Aydiner A and Topuz E: Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma. Med Oncol 23: 543-548, 2006.
18. Sartori E, Laface B, Gadducci A, Maggino T, Zola P, Landoni F and Zanagnolo V: Factors influencing survival in endometrial cancer relapsing patients: a Cooperation Task Force (CTF) study. Int J Gynecol Cancer 13: 458-465, 2003.
19. Ueda Y, Enomoto T, Egawa-Takata T, Miyatake T, Yoshino K, Fujita M, Matsuzaki S, Yokoyama T, Miyoshi Y and Kimura T: Endometrial carcinoma: better prognosis for asymptomatic recurrences than for symptomatic cases found by routine follow-up. Int J Clin Oncol. 2010 Apr 28. [Epub ahead of print].
20. Barlin JN, Puri I and Bristow RE: Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 118: 14-8, 2010.
21. Ueda Y, Miyake T, Egawa-Takata T, Miyatake T, Matsuzaki S, Yokoyama T, Yoshino K, Fujita M, Enomoto T and Kimura T: Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin. Cancer Chemother Pharmacol 2010 Jun 20. [Epub ahead of print].